Modern taxonomy is polyphasic and incorporates genotypic, phenotypic and phylogenetic markers. Genotypic characteristics are based on analysis of DNA or RNA molecules. rRNA is currently regarded as the optimal target for phylogenetic analysis as it is composed of lughly conserved as well as variable domains. At this time direct DNA-sequencing of coding regions for 16s or 23s rRNA is widely performed. Phenotypic procedures include all non-nucleic acid &-rected approaches, e.g. composition of cell wall or cellular fatty acids, whole cell protein analysis etc.
The major Gram-negative pathogens responsible for respiratory infection and mortality in cystic fibrosis (CF) are Pseudomonas amginosa and Burkholdm'a cepm'a. However, Stenohophomonas maltophilia and Alcaligenes xylosoxidans and a few other non-fermenting species are emerging as possibly important patogens due to the improved survial of the patients. All these species are increasingly resistant to most of the available antibiotics which are used extensively in CF patients. Difficult-to-treat strains and multiply resistant strains are therefore becoming an increasing problem in CF centres. Unformnately, cross-infection has been documented with at least I! aeruginosa and B. cepacia in CF centres, in the wards, in the out-patient clinics, in summer-camps and during social activities such as fitness-classes. Even spread of epidemic strains between centres and between countries and between continents has been observed. Such transmissible strains are often multiply resistant due to the selective pressure imposed by the exttensive use of antibiotics in CF patients. The most effective preventive measure has been the use of cohorte isolation technique and high level of hygine in CF centres and during social activities. The cohorting is based on bacteriological examination of sputum, and e.g. patients culture-positive for I! amginosa are kept isolated by geography and/or time &om culture-negative patients.
Social activities such as summer camps are completely avoided in some counmes. We have demonstrated that the sensitivity of retroviruses to human serum is controlled by the expression or alpha 1-3 galactosyl sugar epitopes. We have now made hgh titre packaging cells producing viruses resistant to human serum. We are also attempting to retarget retroviruses to novel surface receptors using an insertion point in the MLV envelope which allows incorporation of an additional receptor binding domain. Our results with chimeric envelopes expressing ligands or single chain antibodies will be &cussed. Finally, our strategies using retroviruses for tumour gene therapy will be presented. These include ex vivo modification of -our c& which are being used in a melanoma vaccine clinical trial and targetting retroviral delivery to tumour cells. First developed for heremtary &orders, gene therapy is also envisioned for the treatment of oncologic and infectious diesases. In the latter case, the genetic modification of cells is aimed at reducing or ablating the replication of a pathogen, resulting in what has been called an "intracellular immunization". In spite of the recent success of pharmaceutical approaches for the management of HIV-induced disease, currently available antiviral drugs are toxic, costly, and need to be administered for an extremely long time, if not for the patients' entire life. Based on this premise, genetic approaches might represent a valid if only complementary approach for the m t m e n t ofHIV mfection. The progress made towards meeting thu; objective, as well as the problems snll remaining and their potential solutions, d be discussed. Objectives: Anunal models have been traditionally used to evaluate the pathogenesis of infectious diseases or to investigate the safety, pharmacokmetics, pharmacodynamics and/or efficacy of antimicrobials. From these models, parameters of antibiotic use have evolved and have helped in the management of specific diseases like meningitis or endocarditis. Recently some antibiotics have been shown to modulate host response. Appropriately designed, experimental models may become powerful tools to explore not only the in vivo antimicrobial activity of antibiotics but their Biological Response Modifiers (BRM) properties.
Acinetobacter
Methods: A murine model of pneumococcal pneumonia was developed i) to study the chronology of events which mediates the progression of the inflammatory response and leads to death, ii) to detect specific markers of disease progression, and iii) to evaluate how antibiotics can interact with the immune system and control this deadly infection.
Results: There was no correlation between the kinetics of cytokines in blood and that observed in bronchoalveolar fluid PAL) or lung. The simultaneous elevation of IL-6 and TNF observed in blood may be a sign of poor prognosis and imminent death, whde in Febrile Neutropenia
